XENE - Company ID 0001582313
The table below shows Xenon Pharmaceuticals Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$279.12M | -$181.39M | -$151.11M | -$101.03M | -$69.50M | -$48.12M |
| Capital expenditure | $799.00K | $3.08M | $5.62M | $2.89M | $2.05M | $2.64M |
| Investing cash flow | $218.00M | $165.00M | -$111.39M | -$293.40M | -$246.77M | -$16.82M |
| Dividends paid | - | - | - | - |
Xenon Pharmaceuticals Inc. reported operating cash flow of -$279.12M for fiscal year 2025. That is down 53.9% from -$181.39M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$28.73M (FY 2017) to -$279.12M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $117.11M | $12.13M | $353.52M | $278.47M | $447.54M | $85.80M |